DelveInsight’s 'Chronic Myelomonocytic Leukemia Pipeline Insight 2024' report provides comprehensive global coverage of pipeline chronic myelomonocytic leukemia therapies in various stages of clinical ...
BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, announced American Society of Hematology ("ASH") accepted ...
Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia. QuANTUM-Wild: A phase 3 ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...
Symptoms of chronic myelomonocytic leukemia (CMML) can include tiredness, bruising and bleeding easily, frequent infections, sweating, and bone pain. Symptoms can depend on the type of CMML. Chronic ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...
HOUSTON - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for ...
DelveInsight’s, “Chronic Myelomonocytic Leukemia - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukemia pipeline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback